Compare Simon Property Group Inc (SPG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Simon Property Group Inc vs TG Therapeutics Inc — how do they compare? Simon Property Group Inc trades at $199.42 (market cap $64.59B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Simon Property Group Inc is far larger — about 7.9× TG Therapeutics Inc's market cap, and Simon Property Group Inc pays a 4.46% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Simon Property Group Inc for 99 Days and TG Therapeutics Inc for 16 Days on average.
| SPG | TGTX | |
|---|---|---|
Market Cap | $64.59B | $8.16B |
Volume | 1,093,907 | 1,735,121 |
Sector | Real Estate | Health |
52-Week High | $236.70 | $59.06 |
52-Week Low | $173.35 | $26.94 |
Typical Hold Time | 99 Days | 16 Days |
Enterprise Value | $93.03B | $8.37B |
Dividend Yield | 4.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPG trades at $199.42, up 0.93% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $6.36B in 2025 and a net income margin of 66.57%, though Q2 2026 EPS missed expectations. Recent news highlights leasing demand strength and a new media network launch, while analyst consensus is a $222.90 price target with 42% buy ratings.
Outlook is mixed: fundamentals are robust with high profitability and dividend yield, but technical weakness and net cash outflows pose risks. Investors may find value in the discounted valuation relative to targets, though sensitivity to interest rates and debt maturities requires caution.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
